2022). During diabetes type 2, there is an inactivation and downregulation of IRS‐1 which was confirmed from our study where the gene expression of IRS‐1 was significantly downregulated in the diabetic group but significantly upregulated with BMEE and glibenclamide treatment. This suggests that BMEE reduces hepatic insulin resistance by upregulating IRS‐1 and increasing insulin action. The gene discussed is INS; the disease is type 2 diabetes mellitus.